ABL Bio
Korea - SeongnamBiotechnology
Focus: ABL Bio is an early-stage Korean antibody and immuno-oncology biotech founded in 2020, focused on developing novel therapeutics for advanced solid tumors. The company is pre-commercial with a wholly Phase 1 pipeline and minimal public visibility.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About ABL Bio
AI assessmentNot HiringNo open roles listed right now. Follow ABL Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ABL001
Advanced Solid TumorsClinical Trials (1)
NCT03292783This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
Phase 1Help build intelligence for ABL Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.